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Acting through its cognate receptor, receptor activator of nuclear factor-kB (RANK), RANK ligand (RANKL) is an essential
mediator of osteoclast function and survival. Preclinical data have now firmly established that blockade of tumor-
induced osteoclastogenesis by RANKL inhibition will not only protect against bone destruction but will also inhibit the
progression of established bone metastases and delay the formation of de novo bone metastases in cancer models. In
patients with bone metastases, skeletal complications are driven by increased osteoclastic activity and may result in
pathological fractures, spinal cord compression and the need for radiotherapy to the bone or orthopedic surgery
(collectively known as skeletal-related events (SREs)). Denosumab, a fully human monoclonal antibody against RANKL,
has been demonstrated to prevent or delay SREs in patients with solid tumors that have metastasized to bone. In
addition to its central role in tumor-induced osteolysis, bone destruction and skeletal tumor progression, there is
emerging evidence for direct pro-metastatic effects of RANKL, independent of osteoclasts. For example, RANKL also
stimulates metastasis via activity on RANK-expressing cancer cells, resulting in increased invasion and migration.
Pharmacological inhibition of RANKL may also reduce bone and lung metastasis through blockade of the direct action of
RANKL on metastatic cells. This review describes these distinct but potentially overlapping mechanisms by which
RANKL may promote metastases.
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Introduction
Receptor activatorof nuclear factor (NF)-kB ligand (RANKL) and
its cognate receptor RANK were initially characterized as
essential factors for osteoclastogenesis (reviewed in Lacey
et al.1). Mice in which either the RANK or RANKL genes are
ablated exhibit severe osteopetrosis and an absence of
osteoclasts.2,3 RANKL and myeloid colony-stimulating factor
are sufficient to generate osteoclasts from their myeloid pre-
cursors.4 Osteoprotegerin (OPG), a decoy receptor for RANKL,
inhibits osteoclasts and acts as a physiological regulator of
bone resorption by counterbalancing RANKL activity.5 The
discovery of RANKL, RANK and OPG revealed the molecular
mechanisms critical for osteoclastogenesis and the physio-
logical control of bone remodeling.
Skeletal metastasis results from reciprocal engagement
between tumor cells and normal host cells of the bone
microenvironment (for example, osteoclasts, stromal cells,
vascular cells and so on; Figure 1). The resultant bone
destruction and skeletal complications are mediated by a
pathologically increased rate of bone remodeling driven by
marked increases in osteoclast activity. This cooperative
interaction between the bone microenvironment and tumor is
known as the vicious cycle and is critical for metastatic
establishment and progression.6 Thus, the increased bone
turnover driven by osteoclastic bone resorption not only
contributes to skeletal morbidity, but has also been hypo-
thesized to contribute to both early tumor colonization and later
progression in bone.Data supporting this hypothesis havebeen
comprehensively described in a recent review by Weilbaecher
et al.7Given that RANKL is essential for osteoclastogenesis, it is
also an attractive therapeutic target for the prevention and
treatment of metastatic bone disease.
The generation of the RANK- and RANKL-knockout mice
revealed that, other than osteopetrosis and peripheral lymph
node agenesis, the only tissue compartment that exhibited
obvious functional defects was the development of the
mammary gland during pregnancy.8 In the absence of RANK or
RANKL, lactation is impaired owing to a defective expansion of
the lobulo-alveolar mammary epithelium at midgestation. This
defect is associated with reduced mammary epithelial pro-
liferation and survival, and it is now understood that RANKL is
themajor paracrine effector of progesterone’smitogenic action
in mouse mammary and human breast epithelium.9,10 RANKL
protein is regulatedbyprogesterone and is expressedwithin the
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estrogen receptor-positive/progesterone receptor-positive
(ERþ /PRþ ) luminal epithelium.10,11 RANKL is positively
correlated with breast proliferation and acts in a paracrine
manner on RANK expressed in proliferating ER /PR breast
cells.9,11 In addition to mediating the mitogenic effect of
progesterone, RANKL also controls the responsiveness of
mammary stem cell and luminal progenitors12 to progester-
one.13,14 These observations provided the initial rationale that
RANKL might also directly stimulate tumor formation and
metastatic progression through activation of epithelial cells.
Here we will review the preclinical in vivo and in vitro
mechanistic evidence that RANKL blockade effectively inhibits
both skeletal and nonskeletal metastasis. We will also review
the clinical trials that have addressed the potential for RANKL
inhibition to delay or prevent skeletal complications or bone
metastases in cancer patients.
Role of RANKL in Pathologically-Induced Osteolysis and
Bone Metastasis
In bone metastasis, RANKL-positive stromal cells have been
observed at the tumor/bone interface adjacent to osteo-
clasts15,16 and associated with tumor-induced osteolysis.17
Early work using co-culture approaches demonstrated that, in
contrast to the observations in progesterone-exposed mam-
mary/breast tissue and primary breast cancer specimens (see
below), breast tumor cells cultured in vitro did not express
RANKL but could provoke increased stromal RANKL
expression, leading to enhanced osteoclast formation.18 This
paradigm of stromal reaction to tumor involvement has been
consistently observed across different model systems. The
molecular mechanisms for upregulation of RANKL within bone
stroma include transcriptional responses to tumor-associated
cytokines and factors including interleukin (IL)-1b, IL-6, IL-8,
IL-11, IL-17, macrophage inflammatory protein-1a, tumor
necrosis factor-a, parathyroid hormone-related protein
(PTHrP), prostaglandin E2 (PGE2) and CXCL13.19,20 Interest-
ingly, stimulation of the sympathetic nervous system has also
been demonstrated to increase RANKL levels within osteoblast
lineage cells.12 Factors produced by tumors such as PTHrP,
IL-1, PGE2, DKK-1 or epidermal growth factor also cause a
decrease in local OPG expression by stromal and osteoblastic
cells, thereby reducing local levels of the natural RANKL
inhibitor.18,21,22 Altogether, the net impact of tumor involvement
on bone is to increase the RANKL:OPG ratio.
Reactive changes in the bone microenvironment to tumor
involvement leads to locally increased RANKL:OPG levels, and
experimental observations in bonemetastasis indicate that this
is the predominant RANKL signal leading to focally aggressive
osteolytic bone destruction. The relative contributions of tumor
cell-expressedRANKLand/orOPG to thenetRANKL:OPG ratio
in bone metastasis is less well defined. Tumor cells themselves
can express OPG, and this can be modulated in the bone by
estrogen signaling.23,24 Although the preponderance of data
indicates little (or variable) RANKL expression on tumor cells
themselves,RANKLexpressionhasbeenoccasionally reported
in primary tumors or tumor cell lines (reviewed in Dougall19),
which would be predicted to cause osteolysis directly, leading
to greater bonemetastasis. Lack of specificity in reagents used
to detect RANKL could explain the disparate observations.
Expression analysis of RANKL in human primary tumors and
potential relationships to metastatic outcomes are discussed
later in this review but it is important to consider that the degree
of RANKL expression observed in the primary tumor may not
reflect the local influences on RANKL levels at the bone
metastatic site. Bone microenvironment signals could induce
RANKL or suppress OPG expression by metastatic tumor cells
using mechanisms similar to those observed in stromal cells.
Experimental methods using either real-time imaging of RANKL
promoter/reporter constructs or careful analysis of host/tumor
mRNA have shown that the bone environment can induce
RANKL within prostate tumor,25 head and neck squamous cell
carcinoma (HNSCC)26 or oral squamous carcinoma27 cells
(OSCC). In addition to cytokines/signals known to stimulate
RANKL production or suppress OPG expression in stroma,
other stimuli present in bone—such as avb3 integrin, CD44,
TGF-b-dependent signaling28 or the hypoxic environment of
bone metastasis,29—may operate on metastatic tumor cells,
leading to enhanced RANKL production. Interestingly, it has
been hypothesized that the reactive skeletal environment may
activate micrometastases to progress into overt bone
metastasis by provoking epithelial-to-mesenchymal transition
(EMT) of tumor cells.30 The expression of RANKL on tumor cells
undergoing EMT, as has been observed in prostate cancer31
and HNSCC,26 may be part of the EMTactivation of metastatic
outgrowth by further exacerbating bone resorption.
The in vitro observations that RANKL expressed on tumor
cells can mediate osteoclastogensis directly without any
requirement forosteoblasts or stromal cells (for example, Zhang
et al.32) suggest that tumor-expressed RANKL, perhaps locally
Figure 1 Interaction with the bone microenvironment supports tumor metastasis. OPG, osteoprotegerin; RANKL, RANK ligand.
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induced within the skeleton, would contribute to bone
metastasis beyond the stromal contribution. However,
experimental evidence demonstrates that any tumor-expres-
sed RANKL has relatively minimal (or variable) contributions
(above and beyond stromal RANKL) to bone metastasis in vivo.
For instance, by comparing a human-specific RANKL antibody
with OPG-Fc, which inhibits both human and mouse RANKL,
Morrissey et al.,33 demonstrated that the stromal RANKL
mediates bone destruction in a human prostate cancer
xenograft model in mice. Using a similar approach in models of
OSCC, Sato et al.34 demonstrated that the stromal contribution
of RANKL was consistently observed, whereas involvement of
tumor cell RANKL in osteolysis was variable. These obser-
vations suggest the potential for tumor-expressed RANKL to
further amplify the osteoclastic response in bone metastasis or
to provoke bone resorption at early steps in bone colonization.
Pharmacological RANKL inhibitors would be active against
RANKL, irrespective of the source (for example, bone stroma,
infiltrating cells and tumor cells), and preclinical experimental
bonemetastasis studies using OPG-Fc or RANK-Fc support an
essential role for RANKL in tumor-associated osteoclasto-
genesis and subsequent osteolytic bone destruction. Tumor-
associated bone destruction in bone metastasis models of
breast, lung, prostate, renal, OSCC, colon and epidermoid
tumors is prevented by pharmacological inhibition of RANKL
(reviewed in Roodman and Dougall35). Most studies have
examined the role of RANKL in bone destruction and pro-
gression of established bone metastases; however, the reci-
procal feedback of tumor cells and bone resorption might also
actively contribute to tumor colonization and metastatic out-
growth, suggesting a role for RANKL at earlier stages of bone
metastasis. Recent evidence from an in vivomodel system has
demonstrated that the localization of MDA-MB-231 breast
cancer cells into bone induces significant contact-dependent
changes of both osteoclast and osteoblast numbers before the
development of bone lesions.36 Defining the molecular
mechanisms responsible for these early events is challenging,
partly because of the limitations in technological identification
of small numbers of tumor cells within bone. Only detailed
histological analysis will reveal the cellular composition of small
tumor foci, and subsequent identification of specific molecules
associated with different cell types within these foci requires
well-validated antibodies. Experimental models have been
utilized to address whether skeletal metastases might be
prevented or delayed through pharmacological blockade of
RANKL and bone turnover in which OPG-Fc treatment was
initiated either simultaneously with or before tumor cell-line
inoculation. RANKL inhibition significantly delayed de novo
formation of skeletal metastases.37 In total, these data indicate
that diverse cancer types employ multiple mechanisms
involving RANKL as a common signaling pathway for tumor-
induced osteolysis. Moreover, RANKL actively contributes to
the vicious cycle of bone metastasis, mediating the processes
of early tumor colonization and progression of bonemetastasis.
Direct (Osteoclast-Independent) Pro-Metastatic Effects of
RANKL
The observation that mouse mammary gland development
during pregnancy is controlled by the intrinsic expression and
functionality of RANK and RANKL within mammary tissue
revealed a critical role for the RANKL pathway in epithelial
biology. These findings provided the first experimental rationale
that RANKL might directly control carcinogenesis and meta-
static progression, distinct from its role in the promotion of
osteoclastogenesis (Figure 2). In fact, the critical direct con-
tribution of RANKL to breast tumor initiation and distant
metastasis has now been demonstrated in vivo. During tumor
formation, RANKL promotes the increased proliferation and
survival of the normal and preneoplastic breast as well as the
proliferative and nonproliferative (regenerative) expansion of
the mammary stem/progenitor cell.38–40 In combination, these
RANKL-dependent mechanisms could expand the pool of
breast epithelial cells undergoing transformation, thereby
increasing mammary cancer risk. In support of this hypothesis,
early RANKL inhibition profoundly blocks mammary tumor
formation.38,39 In addition, both in vitro and in vivo studies have
indicated that RANKL can also promote distant metastasis via
direct effects on RANK-expressing cells (Figure 2). In this
section, we will review the in vivo data supportive of RANKL
promotion of distant metastasis, followed by a review of
mechanistic data suggesting that RANKL promotes metastasis
Figure 2 Mechanisms of RANKL-mediated promotion of metastasis. EMT, epithelial-to-mesenchymal transition; MMP, matrix metalloproteinase; RANKL, RANK ligand.
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by acting directly on RANK-expressing cells, including tumor
cells or a stem/progenitor cell compartment.
Working from the observation that RANKL directly stimulates
B16F10 melanoma cell migration in vitro (see below), Jones
et al.41 tested whether a RANKL inhibitor would block B16F10
metastasis in vivo in an experimental bone metastasis model.
Significant reductions in B16F10 skeletal metastasis were
observed following OPG-Fc treatment, given simultaneously
with tumor cell injection. Two lines of evidence from this
study support the osteoclast-independent nature of this
antimetastatic effect: first, the B16F10 subclone used did not
stimulate a substantial osteoclast reaction to tumor cells in the
bone; and second, in contrast to OPG-Fc, the bisphosphonate
osteoclast inhibitor, zoledronic acid, did not reduce B16F10
bone metastasis. These observations are consistent with a
direct role for RANKL in bone metastasis independent of its
osteoclastogenic activity. This intracardiac experimental
model predominatelydevelops skeletalmetastasis,which limits
any inference on RANKL function toward metastasis to other
sites. Moreover, it is difficult to experimentally dissect
the distinct contributions of osteoclast-dependent and
-independent effects of RANKL on metastasis within the
bone compartment.42
Studies on RANKL function in lung metastasis models avoid
the experimental challenges of discriminating between the
indirect (for example, osteoclast-mediated) vs direct action (for
example, acting on RANK-expressing cells) of RANKL function
in the bone compartment. Data from these models provide
strong evidence for direct promotion of metastasis, distinct
from RANKL effects on osteoclasts. For instance, Gonzalez-
Suarezet al.38 recently evaluatedmousemammary tumor virus-
neu (MMTV-neu) transgenic mice as a model to test the role of
RANKL in spontaneous tumor development and lung metas-
tases. In MMTV-neu mice, RANK-Fc treatment did not change
median time to mammary tumor formation, but reduced the
number of mammary tumors per mouse and significantly
decreased spontaneous lung metastases. Tan et al.43 con-
firmed these findings using complementary methods, obser-
ving significantly fewer (50%) spontaneous lung metastases in
MMTV-neu mice crossed to the RANK-knockout mice vs
MMTV-neucontrols.43Using anorthotopicmammary tumorcell
line (MT2) that spontaneouslymetastasizes to lungs, Tan et al.43
also showed that treatment of mice with RANKL after MT2
tumor grafting to mammary gland increased the incidence and
number of pulmonarymetastases. Finally, knockdown of RANK
within MT2 cells reduced lung metastases and inhibited the
response to RANKL, suggesting that RANKL acted directly on
RANK-expressing tumor cells.
‘Gain-of-function’ experiments in vivo have also provided
evidence that the intrinsic expression of RANK on tumor cells
enhances distant metastasis. For example, overexpression of
RANK in MDA-MB-436 breast tumor cells increased the fre-
quency and size of lung metastases after tail vein injection.44
Similarly, a significantly greater metastatic growth rate in the
bone was observed in high RANK-expressing MDA-MB-231
breast cells compared with RANK-negative MDA-MB-231
cells.45 In both studies, the enhancedmetastatic progression of
RANK-expressing tumor cells at distant sites wasmuch greater
than tumor growth observed upon subcutaneous/orthotopic
injection of tumor cells. In addition, knockdown of RANK
expression in MDA-MB-231 cells prevented the increase in
bone metastasis caused by activation of the sympathetic
nervous system.12 These observations are consistent with the
expression of RANKL at sites of lung and bone metastasis (and
not within subcutaneous tumors) and suggest a direct pro-
metastatic role for RANKL independent of tumor growth.
There is considerable in vitro and in vivo evidence for various
pleiotropic mechanisms that would explain the direct (osteo-
clast-independent) stimulation of metastasis by RANKL.
Multiple recent studies have demonstrated functional RANK
protein expression on the surface of various cancer cell lines,
and in vitro experiments suggest that RANKL stimulation will
directly induce molecular pathways associated with tumor cell
metastasis. Exposure of RANK-expressing human breast, lung,
melanoma and prostate cancer cell lines to RANKL in vitro
resulted in increasedmigrationand invasion throughcollagenor
fibronectin matrices.41,44,46–50 The RANKL-dependent effect is
correlated with upregulation of several factors involved in
migration, angiogenesis and invasion. For instance, RANKL-
dependent changes in MDA-231 breast cancer cells include
matrixmetalloproteinase-1(MMP1),46MMP9, theMMP inducer
EMMPRIN/CD47 and vascular endothelial growth factor
(VEGF).51 TheRANKL-stimulatedmigration and invasionof PC3
cells was correlated with increases in MMP9, IL-6, IL-8, VEGF
and several members of the CXCL-family of chemokines,48
whereas migration and invasion of A549 lung cancer cells
induced by RANKL was correlated with increases in ICAM-1
expression.50 Treatment of MT2 mammary tumor-bearing mice
withRANKL resulted in decreased levels ofmaspin, amammary
serine protease inhibitor known to suppress metastases to
diverse organs such as the lymph node, liver and lung.52 In
addition, EMT is known to be associated with greater motility,
invasion and metastasis, and data suggest that RANKL-
mediated EMT may also stimulate metastatic behavior. Con-
stitutive activation of RANK induces EMT in the breast cell lines
MCF10A and MDA-MB-436. The ability of RANK over-
expression to increase pulmonary metastasis of MDA-MB-436
breast cancer cells was associatedwith EMTand increased cell
migration and anchorage-independent growth.44
Potential for Direct Pro-Metastatic Effect of RANKL via
Action on Stem Cells
In breast cancer, the recently established role of RANKL in the
proliferation and regenerative potential of normal mammary
stem cells or early breast epithelial progenitor cells13,14 sug-
gests that RANKL-dependent activation of a cancer stem cell
(CSC) or tumor-initiating cell (TIC) compartment may influence
metastatic outcomes (Figure 2). The ability of RANKL to control
canonical and noncanonical NF-kB pathways in mammary
epithelia is also suggestive of a link to CSC,53 as these latter
pathways are functionally linked to breast CSC renewal.54
Although unproven, it is hypothesized that CSC, given their
distinct features from the bulk of proliferating tumor cells, are
responsible for metastatic disease and resistance to thera-
pies.55 RANKL clearly regulates the activity of normal stem and
descendant progenitor cells of the breast,13,14,40 but what is the
evidence that this pathway influences breast CSC? After
genetic inactivation of RANK within the mammary epithelial
lineage, the self-renewal capacity of the Lin-CD24þCD49fhi
stem cell-enriched population isolated from mammary tumors
was substantially reduced, correlatingwith theoverall reduction
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in mammary tumor incidence observed in these mice after
medroxyprogesterone acetate and 7,12-dimethylbenz[a]
anthracene treatment.39 As spontaneous metastases do not
occur in this particular model, the association of this stem cell-
enriched population with metastatic potential could not be
determined. Using the experimental model of RANK over-
expression in breast cells, Palafox et al.44 observed increased
expression of breast CSC and basal/stem cell markers and
functional effects consistent with enhanced stem cell activities.
Overexpression of RANK in immortalized but nontumorigenic
MCF-10 cells increased the frequency of CD44þCD24 cells
and the fraction of cells expressing either CD133 or CD10,
phenotypic markers consistent with a stem cell-like fraction.42
RANK overexpression in MCF10A cells confers the ability to
grow in an anchorage-independent manner, a characteristic of
tumor or stem cells. Stem cell functionality was also confirmed
in RANK-overexpressing MCF-10 cells by demonstrating
mammary outgrowth capacity after transplantation in vivo. In
these experiments, RANK overexpression was also associated
with increased tumorigenesis and metastasis suggesting that
the observed increases in CSC numbers and activity may be
relevant. HER-2 expression, a marker associated with breast
CSC in humans56 or TIC in mice53 has now been shown to be
modulated by the bone microenvironment. In a model
mimicking the bone/tumor interactions, a co-culture of
osteoblasts andMCF-7 breast cancer cells caused an increase
in HER-2 that could be blocked by a RANKL inhibitor. RANKL
treatment ofMCF-7 cells increased themammosphere-forming
capacity, consistent with an effect on the stem cell activity.
Analysis of Human RANKL Pathway Expression and
Association with Metastasis
An association of RANK/RANKL levels in tumors with patient
outcome could support the pro-metastatic role of this pathway
as described above. In primary breast cancer, RANK
expression is more commonly observed in ER /PR tumors
(50%) than ERþ /PRþ tumors (18%).44 Higher RANK levels are
positively associated with both higher proliferation index and
pathological grade in primary breast cancer.44 RANK/RANKL
mRNA expression levels (determined by reverse transcription
(RT)-PCR) were able to discriminate between node-negative
and lymph node-positive/distant metastasis patients.42 Higher
RANK mRNA levels in primary breast tumors (n¼ 295) were
significantly correlated with shorter overall survival.57 Similarly,
an analysis of primary breast tumors at the time of diagnosis
(I-SPY 1 Trial; n¼ 149) demonstrated that higher RANK
expression was not only significantly correlated with poorer
recurrence-free survival but was also selectively associated
with bone-dominant vs non-bone-dominant recurrence.58
Using RT-PCR, analysis of primary renal cell carcinoma (RCC)
samples (n¼ 96) indicated that high expression of RANKL or
RANK mRNA was correlated with a significantly shorter dis-
ease-free survival and shorter bone metastasis survival.59 In
addition, lower OPG levels were significantly associated with
poorer bone metastasis survival.
One study has reported that 89% of bone metastasis
samples (total n¼ 74, representing at least 13 different tumor
types) expressedRANKprotein using immunohistochemistry.60
Santini et al.60 also indicated that the incidence of RANKprotein
expression was very high (68%) in primary tumor samples and
the degree/incidence of RANK expression was not significantly
differentwhencomparedbetweenprimary andbonemetastatic
samples. Although this study reports RANK protein expression
in a variety of primary tumors and bone metastases, the extent
of expression observed (for example, 65% for primary breast
tumors) is considerably higher than that reported by our own
groups (o20% for ERþ /PRþ and o50% for ER /PR
primary breast tumors).38,44 It will be important to resolve
whether these discrepancies are due to differences in the
specificity of immunohistochemistry achieved with different
reagents/methodologies, independent scoring systems or
differences in tumor histotype distributions analyzed in the
different studies.
Interestingly, with the exception of the RCC study,59 none of
the aforementioned studies showed any association of primary
tumor RANKL levels, as single variables, with patient outcome.
Thismay reflect relatively low levels and/or infrequent incidence
of RANKL expression in primary tumors or limitations in mRNA
detection for RANKL using differentmRNAdetection platforms.
The progesterone-dependent regulation of RANKL in breast
also indicates that RANKL levels will be dynamically regulated
over the menstrual cycle. Alternatively, RANKL levels in the
primary tumor may not be an important driver of metastasis, as
high baseline RANKL levels are observed in specific tissue sites
of distant metastases, such as peripheral lymph nodes, lung
and bone.61 Activation of the b2 adrenergic receptor, common
in chronic stress and depression, increases RANKL levels in
osteoblasts/bone stromaaswell as in the lungand liver tissue.12
Altogether, these sources could plausibly provide a local pro-
metastatic signal to RANK-expressing cells. The higher
functional expression of RANK in the primary tumor may
therefore be a more critical determinant of metastatic func-
tionality conferred by the RANKL/RANK pathway. Although
there are reports of soluble RANKL in serum of cancer patients,
it is still not clear whether this provides a relevant pathophy-
siological signal for metastasis. Comparative analysis of cir-
culating vs tissue RANKL has indicated that the systemic and
local regulation of RANKL production are discrete pro-
cesses,62,63 suggesting that the local source of RANKL may be
more relevant for metastatic disease.
Clinical Bone Metastasis Studies with Denosumab
Denosumab is a fully human IgG2 monoclonal antibody that
binds humanRANKLwith high affinity.1 In an integrated analysis
of three randomized double-blind phase 3 trials, denosumab
was shown to be superior to the prior standard of care,
zoledronic acid, for the prevention or delay of skeletal com-
plications in patients with advanced cancer and bone
metastases.64 In an additional study in men with nonmetastatic
castration-resistant prostate cancer, denosumab prolonged
bone metastasis-free survival (hazard ratio (HR)¼ 0.85; 95%
confidence interval (CI): 0.73, 0.98; P¼ 0.028) and delayed
the time to first bone metastasis (HR¼ 0.84; 95% CI: 0.71,
0.98; P¼ 0.032) compared with placebo.65 This is the first
clinical study successfully demonstrating that targeting the
bone compartment makes this microenvironment less
hospitable for metastatic establishment and progression.
Taken together, these clinical data demonstrate that RANKL
inhibition can block osteoclast-mediated bone destruction and
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provides a potential new approach for the treatment of bone
metastases.
The abovementioned clinical studies were designed to
address skeletal effects and were not designed to test an
anticancer effect of denosumab. Interestingly, a post hoc
analysis indicated that treatment with denosumab was
associated with improved overall survival compared with
zoledronic acid in a subgroup of patients with lung cancer from
the phase 3 trial of denosumab versus zoledronic acid for the
prevention of skeletal-related events (SREs) in patients with
bone metastases from advanced solid tumors or multiple
myeloma.66,67 The significantly improved survival observed
among patients with advanced lung cancer who received
denosumab could be explained by a greater decrease in bone
turnover achieved with denosumab compared with zoledronic
acid. In addition, themechanisms described in this review, such
as interruption of tumor cell interactions in the bone micro-
environment or direct inhibition of RANKL action on RANK-
expressing lung tumor cells, may also have contributed to this
finding.67
Conclusions and Future Directions
In summary, preclinical studies have demonstrated the central
involvement of RANKL in the establishment and progression of
the bone tumor in addition to tumor-induced bone destruction.
Clinical studies have extended these observations and proven
the causal role of RANKL-mediated osteoclastogenesis in
skeletal complications in patients with existing bone metas-
tases as well as the establishment of new bone metastases. In
addition to expressionwithin thebone stromaandcertain tumor
types, RANKL is now known to be expressedwithin osteocytes
or activated Tcells, although the specific contribution of RANKL
within these cell types to bone metastasis is yet to be
established. Beyond the well-characterized ability to reduce
skeletal metastasis, a review of the recent literature provides
evidence, with both orthotopic and transgenic mouse spon-
taneous metastasis models, that RANKL inhibition reduces
nonskeletal metastasis.
Future preclinical studies will be important to determine
whether any of the individual pro-metastatic mechanisms
directly induced by RANKL on RANK-expressing cells in vitro
would explain the profound ability of RANKL inhibition to block
distant metastasis to nonskeletal sites in vivo. Alternatively, the
direct pro-metastatic effect of RANKL may be due to multiple,
pleiotropic RANKL-dependent responses acting in concert on
RANK-expressing cells. The various effects, including
increased migration/invasion, increased EMT induction,
increased MMP production, increased levels of angiogenic
factors, decreased levels of protease inhibitors, increased
survival of a metastatic stem cell and so on would be predicted
to enhance metastatic behavior independent of tissue site.
Although it is clear that RANK expression on tumor or stem/
progenitor cells is necessary for the pro-metastatic stimuli, the
relevant source(s) of RANKL is still under investigation. Acting in
an autocrine manner, RANKL may stimulate tumor cell
migration and invasion of RANK-expressing cancer cells, as
reported for prostate cancer C42b cells in vitro for instance.68
This autocrine effect may be most relevant in tumor types that
frequently express RANK and RANKL, such as lung adeno-
carcinoma.69 Further analysis of RANK and RANKL expression
in primary or metastatic sites, using well-validated reagents,
may provide additional insights into the relationship of this
pathway and metastatic outcomes in patients and molecular
mechanisms that influence RANK and RANKL expression.
In breast cancer, preclinical observations suggest that
RANKL promotes metastasis via two distinct but overlapping
mechanisms: stimulation of the tumor-induced osteoclasto-
genesis-associated bone metastasis and stimulation of RANK-
expressing tumor cells. In addition, the newly defined role for
RANKL in normal stemandprogenitors cells of thebreast, along
with the known ability of RANK signaling to regulate canonical
and noncanonical NF-kB pathways associated with self-
renewal and activity of CSCs, has prompted the hypothesis that
the profound antimetastatic effect of RANKL inhibition
observed in the MMTV-neu mammary cancer models in vivo
may also include mechanisms acting via decreased activity or
survival of the TIC or metastasis-initiating cells.
The efficacy of RANKL inhibition has been clearly demon-
strated in the prevention of SREs in patients with bone
metastasis caused by a variety of tumors, but given the breast-
specific effects of RANKL, breast cancer may provide a unique
opportunity to investigate both osteoclast-independent and
-dependent pre-metastatic activities of RANKL. Currently,
denosumab is being tested to determine whether RANKL
inhibition prolongs bone metastasis-free survival and disease-
free survival in the adjuvant breast cancer setting.70
Conflict of Interest
WD is an employee of Amgen Inc. The remaining authors
declare no conflict of interest.
Acknowledgements
Weacknowledge TonyPolverino andDanBranstetter for critical
review of the manuscript and Wanda Krall, PhD for editorial
assistance.
References
1. Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK et al. Bench to
bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Nat Rev Drug Discov 2012;11:401–419.
2. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T et al. RANK is
essential for osteoclast and lymph node development. Genes Dev 1999;13:2412–2424.
3. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of
osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature
1999;397:315–323.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al.Osteoprotegerin ligand is
a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176.
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R et al. Osteoprotegerin: a
novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–319.
6. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev
Cancer 2002;2:584–593.
7. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer
2011;11:411–425.
8. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA et al. The osteoclast
differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell
2000;103:41–50.
9. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y et al. Two distinct
mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl
Acad Sci USA 2010;107:2989–2994.
10. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF et al. Progesterone/
RANKL is a major regulatory axis in the human breast. Sci Transl Med 2013;5:182ra55.
11. Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K et al. Progestin effects
on cell proliferation pathways in the postmenopausal mammary gland. Breast Cancer Res
2013;15:R62.
Targeting RANKL in metastasis
WC Dougall et al
6 APRIL 2014 | www.nature.com/bonekey
12. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL et al.
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer
bone metastasis in mice. PLoS Biol 2012;10:e1001363.
13. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al.Control of mammary
stem cell function by steroid hormone signalling. Nature 2010;465:798–802.
14. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al. Progesterone
induces adult mammary stem cell expansion. Nature 2010;465:803–807.
15. Nakamura H, Hiraga T, Ninomiya T, Hosoya A, Fujisaki N, Yoneda T et al. Involvement of cell-
cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human
breast cancer cells in nude mice. J Bone Miner Metab 2008;26:642–647.
16. Ishikuro M, Sakamoto K, Kayamori K, Akashi T, Kanda H, Izumo T et al. Significance of the
fibrous stroma in bone invasion by human gingival squamous cell carcinomas. Bone
2008;43:621–627.
17. Nannuru KC, Futakuchi M, Sadanandam A, Wilson TJ, Varney ML, Myers KJ et al. Enhanced
expression and shedding of receptor activator of NF-kB ligand during tumor-bone interaction
potentiates mammary tumor-induced osteolysis. Clin Exp Metastasis 2009;26:
797–808.
18. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ et al. Breast cancer cells
interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:
4451–4458.
19. Dougall WC. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of
the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res
2012;18:326–335.
20. Sambandam Y, Sundaram K, Liu A, Kirkwood KL, Ries WL, Reddy SV. CXCL13 activation of
c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell
carcinoma tumor-bone microenvironment. Oncogene 2013;32:97–105.
21. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C et al. Breast cancer-derived Dickkopf1
inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer
osteolytic bone metastases. Int J Cancer 2008;123:1034–1042.
22. Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M et al. ADAMTS1 and MMP1
proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
Genes Dev 2009;23:1882–1894.
23. Rachner TD, Schoppet M, Niebergall U, Hofbauer LC. 17beta-Estradiol inhibits osteoprotegerin
production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.
Biochem Biophys Res Commun 2008;368:736–741.
24. Fradet A, Sorel H, Bouazza L, Goehrig D, Depalle B, Bellahcene A et al. Dual function of
ERRalpha in breast cancer and bone metastasis formation: implication of VEGF and
osteoprotegerin. Cancer Res 2011;71:5728–5738.
25. Zhang J, Lu Y, Dai J, Yao Z, Kitazawa R, Kitazawa S et al. In vivo real-time imaging of
TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous
prostate cancer. Prostate 2004;59:360–369.
26. Yamada T, Tsuda M, Takahashi T, Totsuka Y, Shindoh M, Ohba Y. RANKL expression
specifically observed in vivo promotes epithelial mesenchymal transition and tumor pro-
gression. Am J Pathol 2011;178:2845–2856.
27. Zhang X, Junior CR, Liu M, Li F, D’Silva NJ, Kirkwood KL. Oral squamous carcinoma cells
secrete RANKL directly supporting osteolytic bone loss. Oral Oncol 2013;49:119–128.
28. Gupta A, Cao W, Chellaiah MA. Integrin alphavbeta3 and CD44 pathways in metastatic
prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of
NF-kB ligand signaling axis. Mol Cancer 2012;11:66.
29. Tang ZN, Zhang F, Tang P, Qi XW, Jiang J. Hypoxia induces RANK and RANKL expression
by activating HIF-1alpha in breast cancer cells. Biochem Biophys Res Commun 2011;
408:411–416.
30. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone
2011;48:37–43.
31. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G et al.Epithelial to mesenchymal
transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp
Metastasis 2008;25:601–610.
32. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C et al. Osteoprotegerin inhibits prostate
cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin
Invest 2001;107:1235–1244.
33. Morrissey C, Kostenuik PL, Brown LG, Vessella RL, Corey E. Host-derived RANKL is
responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental
bone metastases. BMC Cancer 2007;7:148.
34. Sato K, Lee JW, Sakamoto K, Iimura T, Kayamori K, Yasuda H et al. RANKL synthesized by
both stromal cells and cancer cells plays a crucial role in osteoclastic bone resorption induced
by oral cancer. Am J Pathol 2013;182:1890–1899.
35. Roodman GD, Dougall WC. RANK ligand as a therapeutic target for bone metastases and
multiple myeloma. Cancer Treat Rev 2008;34:92–101.
36. Brown HK, Ottewell PD, Evans CA, Holen I. Location matters: osteoblast and osteoclast
distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp
Metastasis 2012;29:927–938.
37. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ et al. Inhibition of RANKL
blocks skeletal tumor progression and improves survival in a mouse model of breast cancer
bone metastasis. Clin Exp Metastasis 2008;25:119–129.
38. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R et al. RANK
ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Nature 2010;468:103–107.
39. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ et al. Osteoclast dif-
ferentiation factor RANKL controls development of progestin-driven mammary cancer. Nature
2010;468:98–102.
40. Pellegrini P, Cordero A, Gallego M, Dougal WCl, Munoz P, Pujana M et al. Constitutive
activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells
2013;31:1954–1965.
41. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I et al. Regulation
of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692–696.
42. Martin TJ, Mundy GR. Bone metastasis: can osteoclasts be excluded? Nature 2007;445:E19
discussion E19–20.
43. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM et al. Tumour-infiltrating
regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Nature 2011;470:548–553.
44. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A et al. RANK
induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells
and promotes tumorigenesis and metastasis. Cancer Res 2012;72:2879–2888.
45. Blake ML, Tometsko M, Miller R, Jones JC, Dougall WC. RANK expression on breast cancer
cells promotes skeletal metastasis. Clin Exp Metastasis 2013;31:233–245.
46. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R et al. RANKL/RANK/
MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer
cells in vitro. PLoS One 2013;8:e63153.
47. Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Redini F. DU145 human prostate cancer
cells express functional receptor activator of NFkB: new insights in the prostate cancer bone
metastasis process. Bone 2007;40:981–990.
48. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on
RANK-expressing prostate tumor cells and mediates migration and expression of tumor
metastasis genes. Prostate 2008;68:92–104.
49. Zhang L, Teng Y, Zhang Y, Liu J, Xu L, Qu J et al. C-Src-mediated RANKL-induced
breast cancer cell migration by activation of the ERK and Akt pathway. Oncol Lett 2012;
3:395–400.
50. Chen LM, Kuo CH, Lai TY, Lin YM, Su CC, Hsu HH et al. RANKL increases migration of human
lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem
2011;112:933–941.
51. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A et al. Receptor activator
of NF-kB ligand enhances breast cancer-induced osteolytic lesions through upregulation
of extracellular matrix metalloproteinase inducer/CD147. Cancer Res 2010;70:
6150–6160.
52. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL et al. Nuclear cytokine-
activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature
2007;446:690–694.
53. Cao Y, Luo JL, Karin M. IkB kinase alpha kinase activity is required for self-renewal of
ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA
2007;104:15852–15857.
54. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-
canonical NF-kB signaling promotes breast cancer tumor-initiating cells. Oncogene
2013;33:1297–1305.
55. Chu JE, Allan AL. The role of cancer stem cells in the organ tropism of breast cancer
metastasis: a mechanistic balance between the ‘seed’ and the ‘soil’? Int J Breast Cancer
2012;2012:209748.
56. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF et al. HER2 drives luminal
breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of
adjuvant trastuzumab. Cancer Res 2013;73:1635–1646.
57. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A et al. Receptor activator of
NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in
breast cancer patients. PLoS One 2011;6:e19234.
58. Li J, Yau C, Campbell M, Esserman L, Park JW, Rugo HS et al. Correlation of receptor activator
of nuclear factor kappa b (RANK) expression in breast cancer (BC) at the time of diagnosis with
recurrence-free survival (RFS) and risk of bone-dominant metastases (BDM) in the ISPY1 trial.
J Clin Oncol 2012;30(Suppl 27):abstr. 2. (Available at: http://meeting.ascopubs.org/cgi/content/
abstract/30/27_suppl/2?sid=007510f1-1d3c-4894-89ca-8a271491d3de).
59. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R et al. Increased RANKL expression
is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 2009;218:
530–539.
60. Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D et al. Expression pattern of
receptor activator of NFkB (RANK) in a series of primary solid tumors and related bone
metastases. J Cell Physiol 2011;226:780–784.
61. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JM et al. Localization of
RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and
extraskeletal tissues. Bone 1999;25:525–534.
62. Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D et al. The evolving systemic and
local biomarker milieu at different stages of disease progression in rat adjuvant-induced
arthritis. J Clin Immunol 2009;29:158–174.
63. Findlay DM, Atkins GJ. Relationship between serum RANKL and RANKL in bone. Osteoporos
Int 2011;22:2597–2602.
64. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA et al. Superiority of
denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of
3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082–3092.
Targeting RANKL in metastasis
WC Dougall et al
BoneKEy Reports | APRIL 2014 7
65. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al. Denosumab and bone-
metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3,
randomised, placebo-controlled trial. Lancet 2012;379:39–46.
66. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-
blind study of denosumab versus zoledronic acid in the treatment of bone metastases in
patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
J Clin Oncol 2011;29:1125–1132.
67. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C et al. Overall survival improve-
ment in patients with lung cancer and bone metastases treated with denosumab versus zoledronic
acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;7:1823–1829.
68. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML. Shedding of RANKL by tumor-
associated MT1-MMP activates Src-dependent prostate cancer cell migration. Cancer Res
2010;70:5558–5566.
69. Branstetter D, Huang L-Y, Dougal WCl. RANK and RANK-Ligand (RANKL) expression in
primary human lung cancer. J Thorac Oncol 2013;8:S446.
70. Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M et al. Denosumab
versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of
disease recurrence (D-CARE): an international, randomized, double-blind, placebo-controlled
phase 3 clinical trial. Cancer Res 2012;72(24 Suppl):Abstract number OT2-3-03. (Available at:
http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/72/24_MeetingAbstracts/OT2-
3-03?sid=f0763b5d-469a-48da-ae0e-a4c15e0ace37).
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported License. To view a copy
of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Targeting RANKL in metastasis
WC Dougall et al
8 APRIL 2014 | www.nature.com/bonekey
